查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1863392

急性護理綜合症檢測市場：按症候群檢測組合、產品類型、最終用戶、技術和應用分類 - 全球預測（2025-2032 年）

Acute Care Syndromic Testing Market by Syndromic Panel, Product Type, End User, Technology, Application - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，急性照護中的症候群檢測市場將成長至 81.9 億美元，複合年成長率為 10.27%。

關鍵市場統計數據
基準年 2024 37.4億美元
預計年份：2025年 41.2億美元
預測年份 2032 81.9億美元
複合年成長率 (%) 10.27%

簡明扼要地介紹了急性護理中症候群檢測的模式轉移，重點說明臨床整合、診斷速度和系統彈性。

在技​​術進步、臨床工作流程變革以及對診斷速度和準確性日益成長的期望的推動下，急性護理中的症候群檢測領域正經歷著快速且持續的演變。能夠同時檢測多種病原體的症候群檢測正擴大應用於急診和住院環境中，因為在這些環境中，時間緊迫的決策對患者預後至關重要。隨著臨床團隊尋求縮短診斷時間並減少對經驗性治療的依賴，能夠與診療路徑無縫銜接的診斷平台正從概念驗證階段走向實際應用階段。

此外，實驗室基礎設施與照護現場能力之間的交互作用正在重塑採購重點。醫療機構管理者需要在高通量集中檢測與能夠在床邊提供可操作結果的分散式解決方案之間尋求平衡。同時，公共衛生部門和感染預防團隊正在利用症狀數據進行監測和疫情應對，這進一步凸顯了診斷在更廣泛的人口健康策略中的作用。因此，臨床、營運和商業等各部門的相關人員必須在預算有限的情況下，通力合作，以證明其在實際應用中的表現、互通性和臨床效用。

技術、監管和醫療服務模式的變革正在重塑症候群檢測路徑，並加速醫療機構採用照護現場診斷技術。

變革性的變化正在匯聚，重新定義急性護理環境中症候群檢測的開發、部署和維護方式。包括高通量多重檢測、整合式樣本到結果平台以及先進的資料管理功能在內的技術創新，正在降低快速診斷的門檻。這些技術與檢測設計的改進相輔相成，在保持分析靈敏度和特異性的同時，拓寬了病原體檢測範圍，並將臨床應用場景從傳統的呼吸道病原體檢測擴展到神經系統、消化器官系統和性行為感染感染等領域。

同時，醫療服務模式也在不斷調整。急診室、加護病房和門診急診中心都要求更快的檢測結果和更簡化的工作流程，以減少對專業實驗室技術人員的依賴。監管環境和報銷機制也在不斷發展，鼓勵在能夠透過治療效果、抗菌藥物管理和縮短住院時間來證明其臨床價值的情況下，加快相關檢測方法的應用。此外，數位化連接和分析技術使得近乎即時地匯總症候群檢測結果成為可能，從而為加強醫療監測和跨機構公共衛生訊號檢測創造了機會。這些變化共同作用，正迅速將症候群檢測從一種小眾的診斷輔助手段轉變為急性期醫療管理的重要組成部分。

評估2025年美國關稅調整對供應鏈、醫療設備採購、生產獎勵和臨床營運的多面向影響

2025年美國關稅政策調整為參與綜合症檢測的製造商、經銷商和醫療保健機構帶來了新的挑戰。由於進口成本上升和前置作業時間不確定性，原本以即時庫存管理為最佳化策略的供應鏈被迫重新評估籌資策略。為此，許多醫療設備和試劑供應商加快了供應商網路的多元化，並探索區域性生產和組裝方案，以降低進口波動帶來的風險。

因此，醫院和檢測實驗室的採購部門在供應商風險評估方面變得更加嚴格，並優先考慮能夠提供更高生產能力和緊急時應對計畫透明度的長期供應協議。對於平台製造商而言，關稅環境促使他們重新評估定價結構和總體擁有成本 (TCO) 模型，這些模型考慮了物流、海關延誤和庫存持有成本。隨著時間的推移，這些調整影響了產品藍圖和資本分配決策，推動了對模組化設計和可互換耗材的投資，從而減少了對單一來源組件的依賴。

重點，前置作業時間的不確定性影響了高需求檢測試劑套件的供應，為臨床操作帶來了過渡期的摩擦。為應對這項挑戰，實驗室擴大了替代檢測方法的檢驗，加強了與臨床相關人員的合作，並根據病情嚴重程度和感染控制需求確定了檢測的優先順序。儘管產業透過這些調整展現了韌性，但關稅造成的衝擊凸顯了供應鏈透明度、生產靈活性和積極主動的相關人員溝通的戰略重要性。

深入的細分分析揭示了小組、產品類型、最終用戶、技術和應用如何驅動急診護理領域的採用模式和採購決策。

深入了解市場區隔動態對於理解需求領域和不斷變化的採購選擇至關重要。在考慮症候群檢測組合時，由於神經系統感染疾病的嚴重性，中樞神經系統（腦炎/腦膜炎亞群）類別優先考慮高分析靈敏度和快速出結果。區分細菌、寄生蟲和病毒病原體的胃腸道檢測組合需要強大的多重檢測能力和廣泛的檢體相容性。根據細菌、混合和病毒標靶分類的呼吸道檢測組合需要在檢測廣度和通量之間取得平衡，以應對季節性需求高峰。針對披衣菌感染、淋病和皰疹的性行為感染檢測組合需要針對多種檢體類型進行最佳化且具有高特異性的檢測方法。

從產品類型角度來看，從桌上型分析儀到照護現場設備等各類設備組合，直接影響資本支出規劃與實驗室空間決策。同時，套件和試劑（包括試劑盒、多重檢測套組和單組分試劑）則支撐持續的收入來源和供應保障。專注於資料管理和服務合約的軟體和服務，在長期總成本和營運效率方面正發揮著日益重要的作用。最終用戶細分決定了採用路徑：學術機構優先考慮檢測的靈活性和深度，以支援轉化研究；醫院需要檢驗的工作流程和快速的臨床報告；公共衛生實驗室重視監測相容性和高通量能力；而參考實驗室則專注於規模和多重檢測，以服務龐大的客戶網路。技術選擇也影響策略：質譜、微陣列、多重PCR、次世代定序和qPCR等技術在通量、廣度和周轉時間方面各有優劣。最後，諸如鑑別診斷、流行病學、疫情調查、監測和監控等應用領域決定了性能要求以及與臨床和公共衛生資訊系統的整合程度。總而言之，這些細分維度指導著採購優先順序、檢驗策略和相關人員夥伴關係模式。

影響美洲、歐洲、中東和非洲以及亞太地區症候群檢測計畫實施和支持的區域趨勢和戰略考量

區域趨勢對症候群檢測項目的部署策略、監管協調和配套基礎設施有顯著影響。在美洲，就地檢驗的普及和電子健康記錄互聯互通的獎勵正在推動醫院和門診機構採用該技術，而區域供應鏈中心和生產能力則支持快速補貨。在歐洲、中東和非洲地區，不同的法規結構和不均衡的報銷環境要求差異化的商業化策略和客製化服務模式，以適應實驗室整合和集中化的趨勢。在亞太地區，產能的快速擴張、對本地生產的投資以及對強力的公共衛生監測的重視，正在加速高通量和分散式平台的普及。

這些區域差異不僅影響技術的部署地點，也影響企業如何建立其市場推廣和售後支援體系。例如，在本地技術專長有限的地區，服務協議和本地技術支援至關重要；而擁有先進數位健康基礎設施的系統則優先考慮軟體互通性和資料共用標準。此外，採購週期和資金分配因地區而異，這會影響新面板的採用速度和平台升級。了解這些地域差異有助於負責人將分銷策略、本地夥伴關係和培訓計劃與當地的預期和營運實際情況相匹配。

競爭格局和企業策略塑造了急性護理綜合症檢測生態系統中的創新、夥伴關係和商業化。

在症候群檢測生態系統中，各公司的策略正沿著多個維度發展，包括平台差異化、垂直耗材整合以及與實驗室網路和醫療保健系統的策略聯盟。製造商致力於提供端到端解決方案，以最大限度地縮短操作時間、減少故障點，並與實驗室資訊系統和電子健康記錄無縫連接。同時，各公司也投資開發能夠帶來持續收入的耗材產品組合，並採用模組化設計設備，以避免客戶面臨設備過時的風險。

夥伴關係與聯盟模式正逐漸成為加速市場滲透和檢驗產品在不同醫療環境中臨床效用的重要手段。企業擴大與學術機構合作進行臨床檢驗研究，並與公共衛生機構合作，以統一報告格式和監測應用情境。快速反應的技術支援和庫存管理等服務模式也在影響市場競爭，並成為採購決策中的差異化因素。總體而言，市場將青睞那些能夠將強大的分析能力與完善的售後支援、清晰的整合路徑以及靈活的商業條款相結合，從而滿足不同終端用戶需求的企業。

為產業領導者提供切實可行的策略建議，以最佳化供應鏈韌性、加速臨床應用，並使商業模式與醫療保健優先事項保持一致。

尋求獲得永續競爭優勢的行業領導者應優先考慮一系列綜合舉措，涵蓋技術、供應鏈、臨床實施和商業性誠信。首先，投資於平台互通性和開放資料標準將加速臨床整合，並支援下游分析以展現價值。其次，實現製造和物流合作夥伴多元化，並開發區域分銷方案，將最大限度地減少貿易中斷和海關波動對營運的影響。第三，透過真實世界證據研究和以管理為重點的試點項目，將臨床證據的生成融入商業部署，將推動應用並加強與支付方的對話。

此外，經營團隊應考慮模組化定價和服務模式，以降低初始採用門檻，並確保長期總擁有成本的可預測性。加強技術支援和培訓計畫可以減少分散式環境下的採用阻力，並增強臨床醫生的信心。最後，與公共衛生組織和參考網路建立策略合作夥伴關係，可以擴大監測範圍，同時建構聯合檢驗路徑。透過協調產品藍圖、商業模式和強化業務永續營運措施，產業領導者將加速產品推廣，同時降低短期市場波動。

本研究採用綜合調查方法，結合一手訪談、二手文獻回顧、資料三角驗證與檢驗，確保研究結果嚴謹實用。

本報告的分析方法結合了結構化的初步研究、全面的二手文獻綜述和嚴謹的資料三角驗證，以確保得出可靠且可操作的結論。初步研究包括對臨床實驗室主任、採購人員、醫院管理人員和技術開發人員進行深入訪談，以了解其營運實務和決策標準。二級資訊來源包括同行評審的臨床研究、監管指南、技術白皮書和已發布的產品文檔，用於闡明性能特徵和檢驗標準。

資料綜合分析將訪談結果與已記錄的檢驗資料和監管申報文件進行交叉比對，以識別一致的主題和差距。調查方法採用情境分析，探討不同臨床和政策條件下的供應鏈敏感度和實施路徑。品質保證流程包括多輪同儕審查和內部一致性檢查，以確保結論的可靠性，並透明地揭露限制。在適當情況下，也提供了關於普遍適用性和本地適用性的考量，以幫助讀者在其自身營運環境中解讀研究結果。

透過全面的綜合分析，為症候群檢測中的業務決策提供支持，提取對臨床護理、營運和行業戰略的關鍵啟示。

摘要，急性護理中的症候群檢測正從一項新興技術轉變為一項可操作的實踐，為快速臨床決策、感染控制和公共衛生監測奠定基礎。技術的成熟、醫療服務模式的轉變以及政策環境的演變共同推動了該技術的普及應用，而供應鏈和貿易趨勢則凸顯了韌性和多樣化籌資策略的重要性。細分市場分析表明，不同應用領域的臨床優先事項各不相同。神經系統急症需要快速靈敏的檢測，而呼吸系統疾病的激增則需要可擴展的檢測能力和靈活的檢測組合，這就需要採用適應性強的採購和檢驗方法。

展望未來，能夠將技術互通性、穩健的服務模式和實證實施方案結合的相關人員，將更有可能獲得最大的臨床和營運效益。對本地製造、靈活的商業性交付以及與公共衛生和學術機構的夥伴關係進行策略性投資，將進一步提升系統的就緒度。最終，那些能夠將產品設計與實際工作流程相結合並展現出可衡量的臨床影響的機構，將主導向更快速、數據驅動的急診診斷模式的轉變。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 急診越來越多採用多重PCR呼吸道病原體快速鑑定檢測板
  • 透過將人工智慧驅動的演算法與症候群檢測平台結合，加速診斷和預測分析
  • 擴大綜合症檢測範圍，納入醫院抗菌藥物管理中新出現的抗菌藥物抗藥性標記物
  • 監管和報銷政策的變化影響著急性護理機構中照護現場分子綜合症檢測的採用。
  • 擴大次世代定序在醫院症候群監測的應用，可以更快發現微生物集體爆發。
  • 供應商整合和策略聯盟正在推動多種急診護理檢測的標準化和成本效益。
  • 整合數位健康平台的進步使得醫院網路之間能夠即時共用症候群數據。
  • 為了在急診護理中實現快速決策，分散式照護現場分子診斷正日益普及。

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 按症候群和檢測組別分類的急性護理症候群檢測市場

  • 中樞神經系統
    • 腦炎
    • 腦膜炎
  • 消化器官系統
    • 細菌
    • 寄生蟲
    • 病毒性的
  • 呼吸系統
    • 細菌
    • 合成的
    • 病毒性的
  • 性行為感染傳染病
    • 披衣菌感染和感染疾病
    • 皰疹

9. 按產品類型分類的急性護理症候群檢測市場

  • 裝置
    • 工作台
    • 照護端
  • 試劑套件試劑
    • 墨水匣
    • 多重檢測試劑套件
    • 試劑
  • 軟體服務
    • 資料管理
    • 服務協定

第10章 依最終使用者分類的急性照護症候群檢測市場

  • 學術研究機構
  • 醫院
  • 公共衛生研究所
  • 參考檢驗機構

第11章 按技術分類的急性護理症候群檢測市場

  • 質譜分析
  • 微陣列
  • 多重PCR
  • 次世代定序
  • 定量PCR

第12章 按應用分類的急性照護症候群檢測市場

  • 鑑別診斷
  • 流行病學
  • 疫情調查
  • 研究
  • 監視

第13章 各地區急性照護症候群檢測市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 急性照護症候群檢測市場（依組別）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國急性照護症候群檢測市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • bioMerieux SA
    • Cepheid, Inc.
    • Roche Holding AG
    • QIAGEN NV
    • Luminex Corporation
    • Becton Dickinson and Company
    • Hologic, Inc.
    • Seegene, Inc.
    • Quidel Corporation
    • Abbott Laboratories
Product Code: MRR-5A3042B3D68E

The Acute Care Syndromic Testing Market is projected to grow by USD 8.19 billion at a CAGR of 10.27% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 3.74 billion
Estimated Year [2025] USD 4.12 billion
Forecast Year [2032] USD 8.19 billion
CAGR (%) 10.27%

A concise introduction to the shifting paradigm in acute care syndromic testing, highlighting clinical integration, diagnostic speed, and system resilience

The landscape of acute care syndromic testing is experiencing a rapid and sustained evolution driven by technological advances, shifting clinical workflows, and heightened expectations for diagnostic speed and precision. Syndromic testing, which enables simultaneous detection of multiple pathogen classes, is increasingly embedded into urgent care and hospital settings where time-sensitive decisions can materially affect patient outcomes. As clinical teams seek to shorten diagnostic windows and reduce empiric therapy reliance, diagnostic platforms that integrate seamlessly with care pathways are moving from proof-of-concept to operational necessity.

Moreover, the interplay between laboratory infrastructure and point-of-care capabilities is reshaping procurement priorities. Healthcare administrators are balancing the need for high-throughput centralized testing with decentralized solutions that deliver actionable results close to the bedside. In parallel, public health authorities and infection prevention teams are leveraging syndromic data to support surveillance and outbreak response, further emphasizing the role of diagnostics in broader population health strategies. Consequently, stakeholders across clinical, operational, and commercial functions must align around real-world performance, interoperability, and the ability to demonstrate clinical utility within constrained budgets.

Transformative technological, regulatory, and care-delivery shifts reshaping syndromic testing pathways and accelerating point-of-care diagnostics adoption across institutions

Transformative shifts are converging to redefine how syndromic testing is developed, adopted, and sustained in acute care settings. Technological innovations such as highly multiplexed assays, integrated sample-to-answer platforms, and advanced data management capabilities are lowering barriers to rapid diagnosis. These technologies are complemented by improvements in assay design that increase pathogen breadth while preserving analytical sensitivity and specificity, which in turn expands clinical use cases beyond traditional respiratory panels into neurological, gastrointestinal, and sexually transmitted infection applications.

Concurrently, care-delivery models are adapting; emergency departments, intensive care units, and outpatient urgent care centers are demanding faster turnarounds and simplified workflows that reduce dependency on specialized laboratory staff. Regulatory landscapes and reimbursement frameworks are also evolving, encouraging faster adoption when clinical value can be demonstrated through outcomes, antibiotic stewardship, and reduced length of stay. Finally, digital connectivity and analytics are enabling near-real-time aggregation of syndromic results, creating opportunities for improved institutional surveillance and cross-institutional public health signal detection. Taken together, these shifts are accelerating the translation of syndromic testing from niche diagnostic aid to an essential element of acute care management.

Assessing the multifaceted consequences of United States tariff adjustments in 2025 on supply chains, device sourcing, manufacturing incentives, and clinical operations

Adjustments to tariff policies in the United States during 2025 introduced renewed considerations for manufacturers, distributors, and healthcare providers involved with syndromic testing. Supply chains that had been optimized for just-in-time inventory were forced to re-evaluate sourcing strategies as import costs and lead-time uncertainty increased. In response, many device and reagent suppliers accelerated diversification of vendor networks and explored regional manufacturing and assembly options to mitigate exposure to import volatility.

Consequently, procurement teams in hospitals and reference laboratories instituted more stringent supplier risk assessments and prioritized long-term supply agreements that provided greater transparency around capacity and contingency planning. For platform manufacturers, the tariff environment prompted reassessment of pricing structures and total cost of ownership models that account for logistics, customs delays, and inventory carrying costs. Over time, these adjustments influenced product roadmaps and capital allocation decisions, encouraging investments in modular designs and interchangeable consumables that reduce dependency on single-source components.

Importantly, clinical operations experienced transitional friction as lead-time variability affected kit availability for high-demand panels. In response, laboratories expanded validation of alternative assays and intensified collaboration with clinical stakeholders to prioritize testing based on acuity and infection control imperatives. Through these adaptations, the sector demonstrated resilience, but the tariff-induced disruptions underscored the strategic importance of supply chain transparency, manufacturing agility, and proactive stakeholder communication.

Insightful segmentation analysis revealing how panels, product types, end users, technologies, and applications drive adoption patterns and procurement decisions in acute care

A nuanced understanding of segmentation dynamics is essential to appreciate where demand will concentrate and how procurement choices will evolve. When testing is considered by syndromic panel, the central nervous system category, with its encephalitis and meningitis subgroups, prioritizes high analytical sensitivity and rapid turnaround due to the critical nature of neurological infections; gastrointestinal panels that distinguish bacterial, parasitic, and viral etiologies demand robust multiplex capability and specimen versatility; respiratory panels categorized across bacterial, combined, and viral targets must balance breadth with throughput to serve seasonal surges; and sexually transmitted infection panels that profile chlamydia, gonorrhea, and herpes require assays optimized for diverse specimen types and high specificity.

From a product-type perspective, instruments-ranging from benchtop analyzers to point-of-care devices-drive capital planning and lab footprint decisions, while kits and reagents including cartridges, multiplex assay kits, and standalone reagents underpin recurring revenue and supply continuity considerations; software and services focused on data management and service contracts are increasingly decisive for long-term total cost and operational efficiency. End-user segmentation clarifies adoption pathways: academic research institutes prioritize assay flexibility and depth for translational work, hospitals require validated workflows and rapid clinical reporting, public health laboratories emphasize surveillance compatibility and high-throughput capacity, and reference laboratories focus on scale and assay multiplexing to serve broad client networks. Technology choices also shape strategy: options such as mass spectrometry, microarray, multiplex PCR, next-generation sequencing, and qPCR each present distinct trade-offs in throughput, breadth, and turn-around time. Finally, applications including differential diagnosis, epidemiology, outbreak investigation, research, and surveillance determine performance requirements and the degree of integration with clinical and public health information systems. Collectively, these segmentation axes inform procurement prioritization, validation strategies, and partnership models across stakeholders.

Regional dynamics and strategic considerations across the Americas, Europe Middle East & Africa, and Asia-Pacific that influence deployment and support of syndromic testing programs

Regional dynamics materially influence deployment strategies, regulatory alignment, and support infrastructures for syndromic testing programs. In the Americas, incentives for point-of-care expansion and integrated electronic health record connectivity are shaping hospital and outpatient adoption, while regional supply chain hubs and manufacturing capacity support responsive replenishment. Across Europe, the Middle East & Africa, diverse regulatory frameworks and heterogeneous reimbursement environments necessitate differentiated commercialization approaches, as well as tailored service models that account for variable laboratory consolidation and centralization trends. In the Asia-Pacific region, rapid capacity expansion, localized manufacturing investments, and strong public health surveillance priorities have accelerated adoption of both high-throughput and decentralized platforms.

These regional distinctions affect not only where technologies are adopted but how companies structure market entry and post-sale support. For instance, service contracts and local technical support are critical in regions with limited on-site technical expertise, whereas software interoperability and data-sharing standards are prioritized in systems with advanced digital health infrastructures. Moreover, procurement cycles and capital allocation differ across regions, influencing the pace of roll-out for new panels and platform upgrades. Understanding these geographic nuances enables planners to align distribution strategies, local partnerships, and training programs to regional expectations and operational realities.

Competitive landscape and company-level strategies shaping innovation, partnerships, and commercialization in the acute care syndromic testing ecosystem

Corporate strategies within the syndromic testing ecosystem are evolving along multiple vectors, including platform differentiation, vertical integration of consumables, and strategic partnerships with laboratory networks and health systems. Manufacturers focus on delivering end-to-end solutions that minimize hands-on time, reduce failure points, and provide seamless connectivity to laboratory information systems and electronic medical records. At the same time, firms are investing in consumable portfolios that support recurring revenue while designing instruments with modularity to protect customers against obsolescence.

Partnerships and consortium models are emerging as a way to accelerate market penetration and validate clinical utility across diverse care settings. Companies are increasingly collaborating with academic centers for clinical validation studies and with public health agencies to align reporting formats and surveillance use cases. Competitive dynamics are also influenced by service models, as rapid-response technical support and managed inventory programs become differentiators in procurement decisions. Overall, the marketplace favors organizations that can combine robust analytical performance with strong post-sale support, clear integration pathways, and flexible commercial terms that accommodate varied end-user needs.

Actionable strategic recommendations for industry leaders to optimize supply resilience, accelerate clinical adoption, and align commercial models with healthcare priorities

Industry leaders seeking to secure sustainable advantage should prioritize a set of integrated actions that address technology, supply chain, clinical adoption, and commercial alignment. First, investing in platform interoperability and open data standards will accelerate clinical integration and enable downstream analytics that demonstrate value. Second, diversifying manufacturing and logistics partners while building regional distribution contingencies will minimize the operational impact of trade disruptions and customs variability. Third, embedding clinical evidence generation into commercial rollouts-through real-world evidence studies and stewardship-focused pilots-will strengthen adoption and payer conversations.

Additionally, executives should consider modular pricing and service models that lower barriers to initial deployment and offer predictable total cost of ownership over time. Strengthening technical support and training programs will reduce implementation friction and improve clinician confidence in decentralized settings. Finally, cultivating strategic partnerships with public health institutions and reference networks can expand surveillance reach while creating shared validation pathways. By aligning product roadmaps, commercial models, and operational resilience initiatives, industry leaders can accelerate adoption while mitigating near-term market volatility.

Comprehensive research methodology integrating primary interviews, secondary literature, data triangulation, and validation to ensure rigorous and actionable insights

The analytical approach underpinning this report combined structured primary research, exhaustive secondary literature review, and rigorous data triangulation to ensure reliable and actionable findings. Primary research included in-depth interviews with clinical laboratory directors, procurement leads, hospital administrators, and technology developers to capture operational realities and decision-making criteria. Secondary sources comprised peer-reviewed clinical studies, regulatory guidance, technology white papers, and publicly available product documentation to contextualize performance characteristics and validation standards.

Data integration involved cross-checking interview insights against documented validation data and regulatory filings, enabling identification of consistent themes and divergence points. The methodology incorporated scenario analysis to explore supply chain sensitivities and adoption pathways under varying clinical and policy conditions. Quality assurance steps included multiple rounds of expert review and internal consistency checks to ensure that conclusions were robust and that limitations were transparently acknowledged. Where relevant, caveats around generalizability and regional applicability were stated to help readers interpret findings within their operational context.

Concluding synthesis that distills key implications for clinical care, operations, and industry strategy to inform executive decision-making in syndromic testing

In summary, syndromic testing in acute care is transitioning from emerging capability to an operational cornerstone of rapid clinical decision-making, infection control, and public health surveillance. Technological maturation, shifting care delivery models, and evolving policy contexts are collectively driving broader adoption, while supply chain and trade dynamics highlight the importance of resilience and diverse sourcing strategies. Segmentation analyses make clear that clinical priorities differ by application area-neurological emergencies require rapid, high-sensitivity assays while respiratory surges demand scalable throughput and flexible panel composition-necessitating tailored procurement and validation approaches.

Looking forward, stakeholders who combine technological interoperability, robust service models, and evidence-driven adoption programs will be best positioned to capture clinical and operational benefits. Strategic investments in localized manufacturing, flexible commercial offerings, and partnerships with public health and academic institutions will further enhance system preparedness. Ultimately, the organizations that align product design with real-world workflows and demonstrate measurable clinical impact will lead the transition toward more responsive, data-informed acute care diagnostics.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Increasing adoption of multiplex PCR respiratory panels for rapid pathogen identification in emergency departments
  • 5.2. Integration of AI-driven algorithms with syndromic testing platforms to accelerate diagnosis and predictive analytics
  • 5.3. Expansion of syndromic testing panels to include emerging antimicrobial resistance markers for hospital stewardship
  • 5.4. Regulatory and reimbursement shifts influencing adoption of point-of-care molecular syndromic tests in acute settings
  • 5.5. Increasing use of next-generation sequencing in hospital syndromic surveillance to detect microbial outbreaks faster
  • 5.6. Vendor consolidation and strategic partnerships driving standardization and cost efficiencies in multiplex acute care testing
  • 5.7. Advancements in integrated digital health platforms enabling real-time syndromic data sharing across hospital networks
  • 5.8. Shift toward decentralized point-of-care molecular diagnostics to reduce time to actionable acute care decisions

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Acute Care Syndromic Testing Market, by Syndromic Panel

  • 8.1. Central Nervous System
    • 8.1.1. Encephalitis
    • 8.1.2. Meningitis
  • 8.2. Gastrointestinal
    • 8.2.1. Bacterial
    • 8.2.2. Parasitic
    • 8.2.3. Viral
  • 8.3. Respiratory
    • 8.3.1. Bacterial
    • 8.3.2. Combined
    • 8.3.3. Viral
  • 8.4. Sexually Transmitted Infection
    • 8.4.1. Chlamydia Gonorrhea
    • 8.4.2. Herpes

9. Acute Care Syndromic Testing Market, by Product Type

  • 9.1. Instruments
    • 9.1.1. Benchtop
    • 9.1.2. Point Of Care
  • 9.2. Kits Reagents
    • 9.2.1. Cartridges
    • 9.2.2. Multiplex Assay Kits
    • 9.2.3. Reagents
  • 9.3. Software Services
    • 9.3.1. Data Management
    • 9.3.2. Service Contracts

10. Acute Care Syndromic Testing Market, by End User

  • 10.1. Academic Research Institutes
  • 10.2. Hospitals
  • 10.3. Public Health Laboratories
  • 10.4. Reference Laboratories

11. Acute Care Syndromic Testing Market, by Technology

  • 11.1. Mass Spectrometry
  • 11.2. Microarray
  • 11.3. Multiplex Pcr
  • 11.4. Ngs
  • 11.5. Qpcr

12. Acute Care Syndromic Testing Market, by Application

  • 12.1. Differential Diagnosis
  • 12.2. Epidemiology
  • 12.3. Outbreak Investigation
  • 12.4. Research
  • 12.5. Surveillance

13. Acute Care Syndromic Testing Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Acute Care Syndromic Testing Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Acute Care Syndromic Testing Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. bioMerieux SA
    • 16.3.2. Cepheid, Inc.
    • 16.3.3. Roche Holding AG
    • 16.3.4. QIAGEN N.V.
    • 16.3.5. Luminex Corporation
    • 16.3.6. Becton Dickinson and Company
    • 16.3.7. Hologic, Inc.
    • 16.3.8. Seegene, Inc.
    • 16.3.9. Quidel Corporation
    • 16.3.10. Abbott Laboratories

LIST OF FIGURES

  • FIGURE 1. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SYNDROMIC PANEL, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SYNDROMIC PANEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. ACUTE CARE SYNDROMIC TESTING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. ACUTE CARE SYNDROMIC TESTING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ACUTE CARE SYNDROMIC TESTING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SYNDROMIC PANEL, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SYNDROMIC PANEL, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY ENCEPHALITIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY ENCEPHALITIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY ENCEPHALITIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY ENCEPHALITIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY ENCEPHALITIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY ENCEPHALITIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY MENINGITIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY MENINGITIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY MENINGITIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY MENINGITIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY MENINGITIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY MENINGITIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY GASTROINTESTINAL, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY GASTROINTESTINAL, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY GASTROINTESTINAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY GASTROINTESTINAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY GASTROINTESTINAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY GASTROINTESTINAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY GASTROINTESTINAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY GASTROINTESTINAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY BACTERIAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY BACTERIAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY BACTERIAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY BACTERIAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY BACTERIAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY BACTERIAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY PARASITIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY PARASITIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY PARASITIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY PARASITIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY PARASITIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY PARASITIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY VIRAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY VIRAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY VIRAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY VIRAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY VIRAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY VIRAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY RESPIRATORY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY RESPIRATORY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY RESPIRATORY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY RESPIRATORY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY RESPIRATORY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY RESPIRATORY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY RESPIRATORY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY RESPIRATORY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY BACTERIAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY BACTERIAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY BACTERIAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY BACTERIAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY BACTERIAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY BACTERIAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY COMBINED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY COMBINED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY COMBINED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY COMBINED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY COMBINED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY COMBINED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY VIRAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY VIRAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY VIRAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY VIRAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY VIRAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY VIRAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SEXUALLY TRANSMITTED INFECTION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SEXUALLY TRANSMITTED INFECTION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SEXUALLY TRANSMITTED INFECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SEXUALLY TRANSMITTED INFECTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SEXUALLY TRANSMITTED INFECTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SEXUALLY TRANSMITTED INFECTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SEXUALLY TRANSMITTED INFECTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SEXUALLY TRANSMITTED INFECTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY CHLAMYDIA GONORRHEA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY CHLAMYDIA GONORRHEA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY CHLAMYDIA GONORRHEA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY CHLAMYDIA GONORRHEA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY CHLAMYDIA GONORRHEA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY CHLAMYDIA GONORRHEA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY HERPES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY HERPES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY HERPES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY HERPES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY HERPES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY HERPES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY BENCHTOP, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY BENCHTOP, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY BENCHTOP, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY BENCHTOP, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY BENCHTOP, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY BENCHTOP, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY POINT OF CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY POINT OF CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY POINT OF CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY POINT OF CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY POINT OF CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY POINT OF CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY KITS REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY KITS REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY KITS REAGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY KITS REAGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY KITS REAGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY KITS REAGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY KITS REAGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY KITS REAGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY CARTRIDGES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY CARTRIDGES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY CARTRIDGES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY CARTRIDGES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY CARTRIDGES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY CARTRIDGES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY MULTIPLEX ASSAY KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY MULTIPLEX ASSAY KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY MULTIPLEX ASSAY KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY MULTIPLEX ASSAY KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY MULTIPLEX ASSAY KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY MULTIPLEX ASSAY KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY REAGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY REAGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY REAGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY REAGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY REAGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY REAGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SOFTWARE SERVICES, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SOFTWARE SERVICES, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SOFTWARE SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SOFTWARE SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SOFTWARE SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SOFTWARE SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SOFTWARE SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SOFTWARE SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DATA MANAGEMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DATA MANAGEMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DATA MANAGEMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DATA MANAGEMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DATA MANAGEMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DATA MANAGEMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SERVICE CONTRACTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SERVICE CONTRACTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SERVICE CONTRACTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SERVICE CONTRACTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SERVICE CONTRACTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SERVICE CONTRACTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY PUBLIC HEALTH LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY PUBLIC HEALTH LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY PUBLIC HEALTH LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY PUBLIC HEALTH LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY PUBLIC HEALTH LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY PUBLIC HEALTH LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY REFERENCE LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY REFERENCE LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY REFERENCE LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY REFERENCE LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY MASS SPECTROMETRY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY MASS SPECTROMETRY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY MASS SPECTROMETRY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY MASS SPECTROMETRY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY MICROARRAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY MICROARRAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY MICROARRAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY MICROARRAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY MICROARRAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY MICROARRAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY MULTIPLEX PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY MULTIPLEX PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY MULTIPLEX PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY MULTIPLEX PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY MULTIPLEX PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY MULTIPLEX PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY NGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY NGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY NGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY NGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY NGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY NGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY QPCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY QPCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY QPCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY QPCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY QPCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY QPCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DIFFERENTIAL DIAGNOSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DIFFERENTIAL DIAGNOSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DIFFERENTIAL DIAGNOSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DIFFERENTIAL DIAGNOSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DIFFERENTIAL DIAGNOSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DIFFERENTIAL DIAGNOSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY EPIDEMIOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY EPIDEMIOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY EPIDEMIOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY EPIDEMIOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY EPIDEMIOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY EPIDEMIOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY OUTBREAK INVESTIGATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY OUTBREAK INVESTIGATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY OUTBREAK INVESTIGATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY OUTBREAK INVESTIGATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY OUTBREAK INVESTIGATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY OUTBREAK INVESTIGATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY RESEARCH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY RESEARCH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY RESEARCH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY RESEARCH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY RESEARCH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY RESEARCH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SURVEILLANCE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SURVEILLANCE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SURVEILLANCE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SURVEILLANCE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SURVEILLANCE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SURVEILLANCE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 259. AMERICAS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 260. AMERICAS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 261. AMERICAS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SYNDROMIC PANEL, 2018-2024 (USD MILLION)
  • TABLE 262. AMERICAS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SYNDROMIC PANEL, 2025-2032 (USD MILLION)
  • TABLE 263. AMERICAS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2024 (USD MILLION)
  • TABLE 264. AMERICAS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2025-2032 (USD MILLION)
  • TABLE 265. AMERICAS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY GASTROINTESTINAL, 2018-2024 (USD MILLION)
  • TABLE 266. AMERICAS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY GASTROINTESTINAL, 2025-2032 (USD MILLION)
  • TABLE 267. AMERICAS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY RESPIRATORY, 2018-2024 (USD MILLION)
  • TABLE 268. AMERICAS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY RESPIRATORY, 2025-2032 (USD MILLION)
  • TABLE 269. AMERICAS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SEXUALLY TRANSMITTED INFECTION, 2018-2024 (USD MILLION)
  • TABLE 270. AMERICAS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SEXUALLY TRANSMITTED INFECTION, 2025-2032 (USD MILLION)
  • TABLE 271. AMERICAS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 272. AMERICAS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 273. AMERICAS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 274. AMERICAS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 275. AMERICAS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY KITS REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 276. AMERICAS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY KITS REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 277. AMERICAS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SOFTWARE SERVICES, 2018-2024 (USD MILLION)
  • TABLE 278. AMERICAS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SOFTWARE SERVICES, 2025-2032 (USD MILLION)
  • TABLE 279. AMERICAS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 280. AMERICAS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 281. AMERICAS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 282. AMERICAS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 283. AMERICAS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 284. AMERICAS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 285. NORTH AMERICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 286. NORTH AMERICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 287. NORTH AMERICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SYNDROMIC PANEL, 2018-2024 (USD MILLION)
  • TABLE 288. NORTH AMERICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SYNDROMIC PANEL, 2025-2032 (USD MILLION)
  • TABLE 289. NORTH AMERICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2024 (USD MILLION)
  • TABLE 290. NORTH AMERICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2025-2032 (USD MILLION)
  • TABLE 291. NORTH AMERICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY GASTROINTESTINAL, 2018-2024 (USD MILLION)
  • TABLE 292. NORTH AMERICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY GASTROINTESTINAL, 2025-2032 (USD MILLION)
  • TABLE 293. NORTH AMERICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY RESPIRATORY, 2018-2024 (USD MILLION)
  • TABLE 294. NORTH AMERICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY RESPIRATORY, 2025-2032 (USD MILLION)
  • TABLE 295. NORTH AMERICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SEXUALLY TRANSMITTED INFECTION, 2018-2024 (USD MILLION)
  • TABLE 296. NORTH AMERICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY